Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Carla A. Ibrahim-Verbaas is active.

Publication


Featured researches published by Carla A. Ibrahim-Verbaas.


The New England Journal of Medicine | 2013

Variant of TREM2 Associated with the Risk of Alzheimer's Disease

Thorlakur Jonsson; Hreinn Stefansson; Stacy Steinberg; Ingileif Jonsdottir; Palmi V. Jonsson; Jon Snaedal; Sigurbjorn Bjornsson; Johanna Huttenlocher; Allan I. Levey; James J. Lah; Dan Rujescu; Harald Hampel; Ina Giegling; Ole A. Andreassen; Knut Engedal; Ingun Ulstein; Srdjan Djurovic; Carla A. Ibrahim-Verbaas; Albert Hofman; M. Arfan Ikram; Cornelia M. van Duijn; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson

BACKGROUND Sequence variants, including the ε4 allele of apolipoprotein E, have been associated with the risk of the common late-onset form of Alzheimers disease. Few rare variants affecting the risk of late-onset Alzheimers disease have been found. METHODS We obtained the genome sequences of 2261 Icelanders and identified sequence variants that were likely to affect protein function. We imputed these variants into the genomes of patients with Alzheimers disease and control participants and then tested for an association with Alzheimers disease. We performed replication tests using case-control series from the United States, Norway, The Netherlands, and Germany. We also tested for a genetic association with cognitive function in a population of unaffected elderly persons. RESULTS A rare missense mutation (rs75932628-T) in the gene encoding the triggering receptor expressed on myeloid cells 2 (TREM2), which was predicted to result in an R47H substitution, was found to confer a significant risk of Alzheimers disease in Iceland (odds ratio, 2.92; 95% confidence interval [CI], 2.09 to 4.09; P=3.42×10(-10)). The mutation had a frequency of 0.46% in controls 85 years of age or older. We observed the association in additional sample sets (odds ratio, 2.90; 95% CI, 2.16 to 3.91; P=2.1×10(-12) in combined discovery and replication samples). We also found that carriers of rs75932628-T between the ages of 80 and 100 years without Alzheimers disease had poorer cognitive function than noncarriers (P=0.003). CONCLUSIONS Our findings strongly implicate variant TREM2 in the pathogenesis of Alzheimers disease. Given the reported antiinflammatory role of TREM2 in the brain, the R47H substitution may lead to an increased predisposition to Alzheimers disease through impaired containment of inflammatory processes. (Funded by the National Institute on Aging and others.).


Nature Genetics | 2012

Common variants at 12q14 and 12q24 are associated with hippocampal volume

Joshua C. Bis; Charles DeCarli; Albert V. Smith; Fedde van der Lijn; Fabrice Crivello; Myriam Fornage; Stéphanie Debette; Joshua M. Shulman; Helena Schmidt; Velandai Srikanth; Maaike Schuur; Lei Yu; Seung Hoan Choi; Sigurdur Sigurdsson; Benjamin F.J. Verhaaren; Anita L. DeStefano; Jean Charles Lambert; Clifford R. Jack; Maksim Struchalin; Jim Stankovich; Carla A. Ibrahim-Verbaas; Debra A. Fleischman; Alex Zijdenbos; Tom den Heijer; Bernard Mazoyer; Laura H. Coker; Christian Enzinger; Patrick Danoy; Najaf Amin; Konstantinos Arfanakis

Aging is associated with reductions in hippocampal volume that are accelerated by Alzheimers disease and vascular risk factors. Our genome-wide association study (GWAS) of dementia-free persons (n = 9,232) identified 46 SNPs at four loci with P values of <4.0 × 10−7. In two additional samples (n = 2,318), associations were replicated at 12q14 within MSRB3-WIF1 (discovery and replication; rs17178006; P = 5.3 × 10−11) and at 12q24 near HRK-FBXW8 (rs7294919; P = 2.9 × 10−11). Remaining associations included one SNP at 2q24 within DPP4 (rs6741949; P = 2.9 × 10−7) and nine SNPs at 9p33 within ASTN2 (rs7852872; P = 1.0 × 10−7); along with the chromosome 12 associations, these loci were also associated with hippocampal volume (P < 0.05) in a third younger, more heterogeneous sample (n = 7,794). The SNP in ASTN2 also showed suggestive association with decline in cognition in a largely independent sample (n = 1,563). These associations implicate genes related to apoptosis (HRK), development (WIF1), oxidative stress (MSR3B), ubiquitination (FBXW8) and neuronal migration (ASTN2), as well as enzymes targeted by new diabetes medications (DPP4), indicating new genetic influences on hippocampal size and possibly the risk of cognitive decline and dementia.


Proceedings of the National Academy of Sciences of the United States of America | 2014

Common genetic variants associated with cognitive performance identified using the proxy-phenotype method

Cornelius A. Rietveld; Tonu Esko; Gail Davies; Tune H. Pers; Patrick Turley; Beben Benyamin; Christopher F. Chabris; Valur Emilsson; Andrew D. Johnson; James J. Lee; Christiaan de Leeuw; Riccardo E. Marioni; Sarah E. Medland; Michael B. Miller; Olga Rostapshova; Sven J. van der Lee; Anna A. E. Vinkhuyzen; Najaf Amin; Dalton Conley; Jaime Derringer; Cornelia M. van Duijn; Rudolf S. N. Fehrmann; Lude Franke; Edward L. Glaeser; Narelle K. Hansell; Caroline Hayward; William G. Iacono; Carla A. Ibrahim-Verbaas; Vincent W. V. Jaddoe; Juha Karjalainen

Significance We identify several common genetic variants associated with cognitive performance using a two-stage approach: we conduct a genome-wide association study of educational attainment to generate a set of candidates, and then we estimate the association of these variants with cognitive performance. In older Americans, we find that these variants are jointly associated with cognitive health. Bioinformatics analyses implicate a set of genes that is associated with a particular neurotransmitter pathway involved in synaptic plasticity, the main cellular mechanism for learning and memory. In addition to the substantive contribution, this work also serves to show a proxy-phenotype approach to discovering common genetic variants that is likely to be useful for many phenotypes of interest to social scientists (such as personality traits). We identify common genetic variants associated with cognitive performance using a two-stage approach, which we call the proxy-phenotype method. First, we conduct a genome-wide association study of educational attainment in a large sample (n = 106,736), which produces a set of 69 education-associated SNPs. Second, using independent samples (n = 24,189), we measure the association of these education-associated SNPs with cognitive performance. Three SNPs (rs1487441, rs7923609, and rs2721173) are significantly associated with cognitive performance after correction for multiple hypothesis testing. In an independent sample of older Americans (n = 8,652), we also show that a polygenic score derived from the education-associated SNPs is associated with memory and absence of dementia. Convergent evidence from a set of bioinformatics analyses implicates four specific genes (KNCMA1, NRXN1, POU2F3, and SCRT). All of these genes are associated with a particular neurotransmitter pathway involved in synaptic plasticity, the main cellular mechanism for learning and memory.


Stroke | 2014

Predicting Stroke Through Genetic Risk Functions The CHARGE Risk Score Project

Carla A. Ibrahim-Verbaas; Myriam Fornage; Joshua C. Bis; Seung Hoan Choi; Bruce M. Psaty; James B. Meigs; Madhu Rao; Michael A. Nalls; João D. Fontes; Christopher J. O'Donnell; Sekar Kathiresan; Georg Ehret; Caroline S. Fox; Rainer Malik; Martin Dichgans; Helena Schmidt; Jari Lahti; Susan R. Heckbert; Thomas Lumley; Kenneth Rice; Jerome I. Rotter; Kent D. Taylor; Aaron R. Folsom; Eric Boerwinkle; Wayne D. Rosamond; Eyal Shahar; Rebecca F. Gottesman; Peter J. Koudstaal; Najaf Amin; Renske G. Wieberdink

Background and Purpose— Beyond the Framingham Stroke Risk Score, prediction of future stroke may improve with a genetic risk score (GRS) based on single-nucleotide polymorphisms associated with stroke and its risk factors. Methods— The study includes 4 population-based cohorts with 2047 first incident strokes from 22 720 initially stroke-free European origin participants aged ≥55 years, who were followed for up to 20 years. GRSs were constructed with 324 single-nucleotide polymorphisms implicated in stroke and 9 risk factors. The association of the GRS to first incident stroke was tested using Cox regression; the GRS predictive properties were assessed with area under the curve statistics comparing the GRS with age and sex, Framingham Stroke Risk Score models, and reclassification statistics. These analyses were performed per cohort and in a meta-analysis of pooled data. Replication was sought in a case–control study of ischemic stroke. Results— In the meta-analysis, adding the GRS to the Framingham Stroke Risk Score, age and sex model resulted in a significant improvement in discrimination (all stroke: &Dgr;joint area under the curve=0.016, P=2.3×10−6; ischemic stroke: &Dgr;joint area under the curve=0.021, P=3.7×10−7), although the overall area under the curve remained low. In all the studies, there was a highly significantly improved net reclassification index (P<10−4). Conclusions— The single-nucleotide polymorphisms associated with stroke and its risk factors result only in a small improvement in prediction of future stroke compared with the classical epidemiological risk factors for stroke.


Stroke | 2014

Multilocus Genetic Risk Score Associates With Ischemic Stroke in Case–Control and Prospective Cohort Studies

Rainer Malik; Steve Bevan; Michael A. Nalls; Elizabeth G. Holliday; William J. Devan; Yu Ching Cheng; Carla A. Ibrahim-Verbaas; Benjamin F.J. Verhaaren; Joshua C. Bis; Aron Y. Joon; Anita L. De Stefano; Myriam Fornage; Bruce M. Psaty; M. Arfan Ikram; Lenore J. Launer; Cornelia M. van Duijn; Pankaj Sharma; Braxton D. Mitchell; Jonathan Rosand; James F. Meschia; Christopher Levi; Peter M. Rothwell; Cathie Sudlow; Hugh S. Markus; Sudha Seshadri; Martin Dichgans

Background and Purpose— Genome-wide association studies have revealed multiple common variants associated with known risk factors for ischemic stroke (IS). However, their aggregate effect on risk is uncertain. We aimed to generate a multilocus genetic risk score (GRS) for IS based on genome-wide association studies data from clinical-based samples and to establish its external validity in prospective population-based cohorts. Methods— Three thousand five hundred forty-eight clinic-based IS cases and 6399 controls from the Wellcome Trust Case Control Consortium 2 were used for derivation of the GRS. Subjects from the METASTROKE consortium served as a replication sample. The validation sample consisted of 22 751 participants from the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium. We selected variants that had reached genome-wide significance in previous association studies on established risk factors for IS. Results— A combined GRS for atrial fibrillation, coronary artery disease, hypertension, and systolic blood pressure significantly associated with IS both in the case–control samples and in the prospective population-based studies. Subjects in the top quintile of the combined GRS had >2-fold increased risk of IS compared with subjects in the lowest quintile. Addition of the combined GRS to a simple model based on sex significantly improved the prediction of IS in the combined clinic-based samples but not in the population-based studies, and there was no significant improvement in net reclassification. Conclusions— A multilocus GRS based on common variants for established cardiovascular risk factors was significantly associated with IS both in clinic-based samples and in the general population. However, the improvement in clinical risk prediction was found to be small.


European Journal of Human Genetics | 2014

The sex-specific associations of the aromatase gene with Alzheimer’s disease and its interaction with IL10 in the Epistasis Project

Christopher Medway; Onofre Combarros; Mario Cortina-Borja; Helen T Butler; Carla A. Ibrahim-Verbaas; Renée F.A.G. de Bruijn; Peter J. Koudstaal; Cornelia M. van Duijn; M. Arfan Ikram; Ignacio Mateo; Pascual Sánchez-Juan; Michael G Lehmann; Reinhard Heun; Heike Kölsch; Panos Deloukas; Naomi Hammond; Eliecer Coto; Victoria Alvarez; Patrick Gavin Kehoe; Rachel Barber; Gordon Wilcock; Kristelle Brown; Olivia Belbin; Donald Warden; A. David Smith; Kevin Morgan; Donald J Lehmann

Epistasis between interleukin-10 (IL10) and aromatase gene polymorphisms has previously been reported to modify the risk of Alzheimer’s disease (AD). However, although the main effects of aromatase variants suggest a sex-specific effect in AD, there has been insufficient power to detect sex-specific epistasis between these genes to date. Here we used the cohort of 1757 AD patients and 6294 controls in the Epistasis Project. We replicated the previously reported main effects of aromatase polymorphisms in AD risk in women, for example, adjusted odds ratio of disease for rs1065778 GG=1.22 (95% confidence interval: 1.01–1.48, P=0.03). We also confirmed a reported epistatic interaction between IL10 rs1800896 and aromatase (CYP19A1) rs1062033, again only in women: adjusted synergy factor=1.94 (1.16–3.25, 0.01). Aromatase, a rate-limiting enzyme in the synthesis of estrogens, is expressed in AD-relevant brain regions ,and is downregulated during the disease. IL-10 is an anti-inflammatory cytokine. Given that estrogens have neuroprotective and anti-inflammatory activities and regulate microglial cytokine production, epistasis is biologically plausible. Diminishing serum estrogen in postmenopausal women, coupled with suboptimal brain estrogen synthesis, may contribute to the inflammatory state, that is a pathological hallmark of AD.


Journal of Alzheimer's Disease | 2016

Evaluation of a Genetic Risk Score to Improve Risk Prediction for Alzheimer’s Disease

Vincent Chouraki; Christiane Reitz; Fleur Maury; Joshua C. Bis; Céline Bellenguez; Lei Yu; Johanna Jakobsdottir; Shubhabrata Mukherjee; Hieab H.H. Adams; Seung Hoan Choi; Eric B. Larson; Annette L. Fitzpatrick; André G. Uitterlinden; Philip L. De Jager; Albert Hofman; Vilmundur Gudnason; Badri N. Vardarajan; Carla A. Ibrahim-Verbaas; Sven J. van der Lee; Oscar L. Lopez; Jean-François Dartigues; Claudine Berr; Philippe Amouyel; David A. Bennett; Cornelia van Duijn; Anita L. DeStefano; Lenore J. Launer; M. Arfan Ikram; Paul K. Crane; Jean-Charles Lambert

Effective prevention of Alzheimers disease (AD) requires the development of risk prediction tools permitting preclinical intervention. We constructed a genetic risk score (GRS) comprising common genetic variants associated with AD, evaluated its association with incident AD and assessed its capacity to improve risk prediction over traditional models based on age, sex, education, and APOEɛ4. In eight prospective cohorts included in the International Genomics of Alzheimers Project (IGAP), we derived weighted sum of risk alleles from the 19 top SNPs reported by the IGAP GWAS in participants aged 65 and older without prevalent dementia. Hazard ratios (HR) of incident AD were estimated in Cox models. Improvement in risk prediction was measured by the difference in C-index (Δ-C), the integrated discrimination improvement (IDI) and continuous net reclassification improvement (NRI>0). Overall, 19,687 participants at risk were included, of whom 2,782 developed AD. The GRS was associated with a 17% increase in AD risk (pooled HR = 1.17; 95% CI =   [1.13-1.21] per standard deviation increase in GRS; p-value =  2.86×10-16). This association was stronger among persons with at least one APOEɛ4 allele (HRGRS = 1.24; 95% CI =   [1.15-1.34]) than in others (HRGRS = 1.13; 95% CI =   [1.08-1.18]; pinteraction = 3.45×10-2). Risk prediction after seven years of follow-up showed a small improvement when adding the GRS to age, sex, APOEɛ4, and education (Δ-Cindex =  0.0043 [0.0019-0.0067]). Similar patterns were observed for IDI and NRI>0. In conclusion, a risk score incorporating common genetic variation outside the APOEɛ4 locus improved AD risk prediction and may facilitate risk stratification for prevention trials.


PLOS Genetics | 2016

Rare Functional Variant in TM2D3 is Associated with Late-Onset Alzheimer's Disease

Johanna Jakobsdottir; Sven J. van der Lee; Joshua C. Bis; Vincent Chouraki; David Li-Kroeger; Shinya Yamamoto; Megan L. Grove; Adam C. Naj; Maria Vronskaya; Jose L. Salazar; Anita L. DeStefano; Jennifer A. Brody; Albert V. Smith; Najaf Amin; Rebecca Sims; Carla A. Ibrahim-Verbaas; Seung-Hoan Choi; Claudia L. Satizabal; Oscar L. Lopez; Alexa Beiser; M. Arfan Ikram; Melissa Garcia; Caroline Hayward; Tibor V. Varga; Samuli Ripatti; Paul W. Franks; Göran Hallmans; Olov Rolandsson; Jan-Hakon Jansson; David J. Porteous

We performed an exome-wide association analysis in 1393 late-onset Alzheimer’s disease (LOAD) cases and 8141 controls from the CHARGE consortium. We found that a rare variant (P155L) in TM2D3 was enriched in Icelanders (~0.5% versus <0.05% in other European populations). In 433 LOAD cases and 3903 controls from the Icelandic AGES sub-study, P155L was associated with increased risk and earlier onset of LOAD [odds ratio (95% CI) = 7.5 (3.5–15.9), p = 6.6x10-9]. Mutation in the Drosophila TM2D3 homolog, almondex, causes a phenotype similar to loss of Notch/Presenilin signaling. Human TM2D3 is capable of rescuing these phenotypes, but this activity is abolished by P155L, establishing it as a functionally damaging allele. Our results establish a rare TM2D3 variant in association with LOAD susceptibility, and together with prior work suggests possible links to the β-amyloid cascade.


Journal of Neurology, Neurosurgery, and Psychiatry | 2013

Intensity of human prion disease surveillance predicts observed disease incidence

Genevieve M. Klug; Handan Wand; Marion Simpson; Alison Boyd; Matthew Law; Colin L. Masters; Radoslav Mateǰ; Rachel Howley; Michael Farrell; Maren Breithaupt; Inga Zerr; Cornelia van Duijn; Carla A. Ibrahim-Verbaas; Jan Mackenzie; Robert G. Will; Jean-Philippe Brandel; Annick Alpérovitch; Herbert Budka; Gabor G. Kovacs; Gerard H. Jansen; Michael Coulthard; Steven J. Collins

Background Prospective national screening and surveillance programmes serve a range of public health functions. Objectively determining their adequacy and impact on disease may be problematic for rare disorders. We undertook to assess whether objective measures of disease surveillance intensity could be developed for the rare disorder sporadic Creutzfeldt–Jakob disease (CJD) and whether such measures correlate with disease incidence. Method From 10 countries with national human prion disease surveillance centres, the annual number of suspected prion disease cases notified to each national unit (n=17 610), referrals for cerebrospinal fluid (CSF) 14-3-3 protein diagnostic testing (n=28 780) and the number of suspect cases undergoing diagnostic neuropathological examination (n=4885) from 1993 to 2006 were collected. Age and survey year adjusted incidence rate ratios with 95% CIs were estimated using Poisson regression models to assess risk factors for sporadic, non-sporadic and all prion disease cases. Results Age and survey year adjusted analysis showed all three surveillance intensity measures (suspected human prion disease notifications, 14-3-3 protein diagnostic test referrals and neuropathological examinations of suspect cases) significantly predicted the incidence of sporadic CJD, non-sporadic CJD and all prion disease. Conclusions Routine national surveillance methods adjusted as population rates allow objective determination of surveillance intensity, which correlates positively with reported incidence for human prion disease, especially sporadic CJD, largely independent of national context. The predictive relationship between surveillance intensity and disease incidence should facilitate more rapid delineation of aberrations in disease occurrence and assessment of the adequacy of disease monitoring by national registries.


European Journal of Human Genetics | 2014

The dystrophin gene and cognitive function in the general population

Dina Vojinovic; Hieab H.H. Adams; Sven J. van der Lee; Carla A. Ibrahim-Verbaas; Rutger W. W. Brouwer; Mirjam C. G. N. van den Hout; Edwin Oole; Jeroen van Rooij; André G. Uitterlinden; Albert Hofman; Wilfred van IJcken; Annemieke Aartsma-Rus; Gert-Jan B. van Ommen; M. Arfan Ikram; Cornelia M. van Duijn; Najaf Amin

The aim of our study is to investigate whether single-nucleotide dystrophin gene (DMD) variants associate with variability in cognitive functions in healthy populations. The study included 1240 participants from the Erasmus Rucphen family (ERF) study and 1464 individuals from the Rotterdam Study (RS). The participants whose exomes were sequenced and who were assessed for various cognitive traits were included in the analysis. To determine the association between DMD variants and cognitive ability, linear (mixed) modeling with adjustment for age, sex and education was used. Moreover, Sequence Kernel Association Test (SKAT) was used to test the overall association of the rare genetic variants present in the DMD with cognitive traits. Although no DMD variant surpassed the prespecified significance threshold (P<1 × 10−4), rs147546024:A>G showed strong association (β=1.786, P-value=2.56 × 10−4) with block-design test in the ERF study, while another variant rs1800273:G>A showed suggestive association (β=−0.465, P-value=0.002) with Mini-Mental State Examination test in the RS. Both variants are highly conserved, although rs147546024:A>G is an intronic variant, whereas rs1800273:G>A is a missense variant in the DMD which has a predicted damaging effect on the protein. Further gene-based analysis of DMD revealed suggestive association (P-values=0.087 and 0.074) with general cognitive ability in both cohorts. In conclusion, both single variant and gene-based analyses suggest the existence of variants in the DMD which may affect cognitive functioning in the general populations.

Collaboration


Dive into the Carla A. Ibrahim-Verbaas's collaboration.

Top Co-Authors

Avatar

Cornelia van Duijn

Erasmus University Medical Center

View shared research outputs
Top Co-Authors

Avatar

Maaike Schuur

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Cornelia M. van Duijn

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

M. Arfan Ikram

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Najaf Amin

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Joshua C. Bis

University of Washington

View shared research outputs
Top Co-Authors

Avatar

Monique M.B. Breteler

German Center for Neurodegenerative Diseases

View shared research outputs
Top Co-Authors

Avatar

Sven J. van der Lee

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lenore J. Launer

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge